New Nanoscale Drug Delivery Systems and their Application to HIV/AIDS treatment
新型纳米药物输送系统及其在艾滋病毒/艾滋病治疗中的应用
基本信息
- 批准号:EP/I038721/1
- 负责人:
- 金额:$ 111.95万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Research Grant
- 财政年份:2011
- 资助国家:英国
- 起止时间:2011 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
HIV/AIDS is described by the World Health Organisation as a global pandemic. Estimates show that over 25 million people have died since 1981 and over 33 million people including adults and children are currently living with the disease. In 2005, AIDS claimed an estimated 3.3 million lives globally, including more than 570,000 children. The prevalence of HIV/AIDS continues to increase and it is expected that over 90 million will ultimately be infected in Africa alone. The UK had the highest growth in HIV/AIDS infection in western Europe in the period between 2001 - 2007 with a 64% increase. HIV treatment suffers from many issues including the need for patient compliance with a very strict regime of medication. HIV mutation leads to resistance to existing therapies but the ability of therapies to target HIV in the body is critical to the success of medication. HIV resides in various sites throughout the body but there are both cellular and tissue sites which are particularly difficult for drugs to reach. These so called 'sanctuary sites' have the potential to be targeted by particles of drug, rather than dissolved drug molecules. Cancer research has shown the benefits of particulate nanomedicine drug delivery approaches. The use of nanoscale polymer carriers which act as vehicles to transport and deliver poorly soluble drugs to the desired site of action, has been beneficial for tumour targeting as the particle nature of the nanomedicine drives the accumulation in tumour tissues. Cellular and tissue sanctuary sites in HIV infection have been widely speculated to also be ideal candidates for particle-based approaches but there has been limited work in this area.Branched polymers may operate as particle-like drug delivery vehicles and many have been shown to have therapeutic advantages. The best materials are however very expensive to synthesise and would not be viable for treatments in populations such as the sub-Saharan regions (over 20 milllion HIV infections) where cost is a critical component of treatment choice. The University of Liverpool has developed a new class of materials, Polydendrons, that offer many of the benefits of the most sophisticated branched polymers, but can be produced relatively cheaply. In early work, prototype materials have been produced with particle sizes of >40nm and encapsulation capabilities. These materials are unique and still at a very early stage of development. This proposal will simultaneously explore the synthesis of Polydendrons and their ability to intervene in HIV treatments. They will be studied as drug carriers of specific size, shape and surface functionality and their ability to target HIV in sanctuary sites will be established. A collaboration between the departments of Chemistry and Molecular and Clinical Pharmacology over 4.5 years is proposed with input from global pharmaceutical companies and HIV clinicians. This approach of material synthesis with integrated pharmacology will considerably accelerate the development of potential new therapies leading to a leading position for the UK that will be applicable to other health issues such as cancer, tuberculosis and hepatitis C.
世界卫生组织将艾滋病毒/艾滋病描述为全球流行病。据估计,自 1981 年以来已有超过 2500 万人死亡,目前包括成人和儿童在内的超过 3300 万人患有这种疾病。 In 2005, AIDS claimed an estimated 3.3 million lives globally, including more than 570,000 children.艾滋病毒/艾滋病的流行率持续上升,预计仅在非洲就有超过 9000 万人最终受到感染。 2001年至2007年期间,英国的艾滋病毒/艾滋病感染率是西欧国家中增长最快的,增长了64%。 HIV治疗面临许多问题,包括患者需要遵守非常严格的用药制度。 HIV 突变会导致对现有疗法产生耐药性,但针对体内 HIV 的疗法的能力对于药物治疗的成功至关重要。 HIV 存在于全身各个部位,但有些细胞和组织部位是药物特别难以到达的。这些所谓的“避难所”有可能成为药物颗粒而不是溶解的药物分子的目标。癌症研究已经证明了颗粒纳米药物输送方法的好处。使用纳米级聚合物载体作为载体将难溶性药物运输和递送到所需的作用位点,有利于肿瘤靶向,因为纳米药物的颗粒性质会促进在肿瘤组织中的积累。 HIV感染中的细胞和组织避难所位点被广泛推测也是基于颗粒的方法的理想候选者,但该领域的工作有限。支化聚合物可以作为颗粒状药物输送载体,并且许多支化聚合物已被证明具有治疗优势。然而,最好的材料合成起来非常昂贵,并且不适用于撒哈拉以南地区(超过 2000 万艾滋病毒感染者)等人群的治疗,在这些地区,成本是治疗选择的关键组成部分。利物浦大学开发了一种新型材料——Polydendrons,它具有最复杂的支化聚合物的许多优点,但生产成本相对较低。在早期工作中,原型材料已生产出粒径 >40nm 且具有封装能力的材料。这些材料是独特的,并且仍处于开发的早期阶段。该提案将同时探索 Polydendrons 的合成及其干预艾滋病毒治疗的能力。它们将作为具有特定尺寸、形状和表面功能的药物载体进行研究,并将确定它们在庇护所中靶向艾滋病毒的能力。根据全球制药公司和 HIV 临床医生的意见,化学系与分子和临床药理学系之间提议进行 4.5 年的合作。这种材料合成与综合药理学的方法将大大加速潜在新疗法的开发,从而使英国处于领先地位,该疗法将适用于癌症、结核病和丙型肝炎等其他健康问题。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Architectural control of polystyrene physical properties using branched anionic polymerization initiated at ambient temperature
- DOI:10.1002/pol.20200143
- 发表时间:2020-05-15
- 期刊:
- 影响因子:3.4
- 作者:Alhilfi, Tamara;Chambon, Pierre;Rannard, Steve P.
- 通讯作者:Rannard, Steve P.
Modulated release from implantable ocular silicone oil tamponade drug reservoirs.
- DOI:10.1002/pola.28973
- 发表时间:2018-04-15
- 期刊:
- 影响因子:0
- 作者:Cauldbeck H;Le Hellaye M;McDonald TO;Long M;Williams RL;Rannard SP;Kearns VR
- 通讯作者:Kearns VR
Inaugural Meeting of the British Society for Nanomedicine
英国纳米医学学会成立大会
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:Andrew Owen (Author)
- 通讯作者:Andrew Owen (Author)
Exploring the homogeneous controlled radical polymerisation of hydrophobic monomers in anti-solvents for their polymers: RAFT and ATRP of various alkyl methacrylates in anhydrous methanol to high conversion and low dispersity
- DOI:10.1039/c5py00791g
- 发表时间:2015-01-01
- 期刊:
- 影响因子:4.6
- 作者:Dwyer, A. B.;Chambon, P.;Rannard, S. P.
- 通讯作者:Rannard, S. P.
Novel surface modification of thiol terminated dendrons with polyethylene glycol using Michael addition thiol-ene click chemistry
使用迈克尔加成硫醇-烯点击化学用聚乙二醇对硫醇封端的树枝进行新型表面修饰
- DOI:
- 发表时间:2012
- 期刊:
- 影响因子:0
- 作者:Auty Sam E.
- 通讯作者:Auty Sam E.
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven Rannard其他文献
Steven Rannard的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven Rannard', 18)}}的其他基金
Insights into Degradable Branched Step-growth Polymers using Transfer-dominated Branching Radical Telomerisation
使用转移主导的支化自由基调聚对可降解支化逐步增长聚合物的见解
- 批准号:
EP/X010864/1 - 财政年份:2023
- 资助金额:
$ 111.95万 - 项目类别:
Research Grant
New Polymers from Multi-Vinyl Monomer Homopolymerisation
来自多乙烯基单体均聚的新型聚合物
- 批准号:
EP/R010544/1 - 财政年份:2017
- 资助金额:
$ 111.95万 - 项目类别:
Research Grant
Integrated radiomaterials chemistry for simultaneous multi-component tracking of nanomedicines in biological matrices
集成放射性材料化学,用于同时跟踪生物基质中纳米药物的多成分
- 批准号:
EP/L02635X/1 - 财政年份:2014
- 资助金额:
$ 111.95万 - 项目类别:
Research Grant
Towards NanoMedicine Interventions for HIV/AIDS
针对艾滋病毒/艾滋病的纳米医学干预
- 批准号:
EP/K002201/1 - 财政年份:2012
- 资助金额:
$ 111.95万 - 项目类别:
Research Grant
Non-Attrition HAART nanoparticle therapies for HIV/AIDS Drug Delivery
用于 HIV/AIDS 药物输送的非损耗 HAART 纳米颗粒疗法
- 批准号:
EP/G066272/1 - 财政年份:2009
- 资助金额:
$ 111.95万 - 项目类别:
Research Grant
相似海外基金
Improving Fragment Based Drug Discovery and the Development of Tools for Chemical Biology through Nanoscale Encapsulation and NMR Spectroscopy
通过纳米级封装和核磁共振波谱改善基于片段的药物发现和化学生物学工具的开发
- 批准号:
10419416 - 财政年份:2022
- 资助金额:
$ 111.95万 - 项目类别:
Improving Fragment Based Drug Discovery and the Development of Tools for Chemical Biology through Nanoscale Encapsulation and NMR Spectroscopy
通过纳米级封装和核磁共振波谱改善基于片段的药物发现和化学生物学工具的开发
- 批准号:
10707914 - 财政年份:2022
- 资助金额:
$ 111.95万 - 项目类别:
Nanoscale drug carriers for the treatment of Acute Respiratory Distress Syndrome (ARDS).
用于治疗急性呼吸窘迫综合征(ARDS)的纳米药物载体。
- 批准号:
10461706 - 财政年份:2020
- 资助金额:
$ 111.95万 - 项目类别:
Nanoscale drug carriers for the treatment of Acute Respiratory Distress Syndrome (ARDS).
用于治疗急性呼吸窘迫综合征(ARDS)的纳米药物载体。
- 批准号:
10693409 - 财政年份:2020
- 资助金额:
$ 111.95万 - 项目类别:
Nanoscale drug carriers for the treatment of Acute Respiratory Distress Syndrome (ARDS).
用于治疗急性呼吸窘迫综合征(ARDS)的纳米药物载体。
- 批准号:
10480920 - 财政年份:2020
- 资助金额:
$ 111.95万 - 项目类别:
Transforming Drug Discovery by Nanoscale Chemistry and Screening Enabled by Machine Learning
通过纳米级化学和机器学习筛选来改变药物发现
- 批准号:
105076 - 财政年份:2019
- 资助金额:
$ 111.95万 - 项目类别:
Feasibility Studies
Nanoscale Encapsulation for Fragment Based Drug Discovery
用于基于片段的药物发现的纳米级封装
- 批准号:
9241998 - 财政年份:2016
- 资助金额:
$ 111.95万 - 项目类别:
Development of a new anti-cancer drug delivery platform using acoustically activated nanoscale and microscale agents
使用声激活纳米级和微米级药剂开发新型抗癌药物输送平台
- 批准号:
315883 - 财政年份:2014
- 资助金额:
$ 111.95万 - 项目类别:
Fellowship Programs
Nanoscale characterisation of the dynamics of artificial lipid membranes - model systems for drug binding studies
人工脂质膜动力学的纳米级表征 - 用于药物结合研究的模型系统
- 批准号:
DP110103032 - 财政年份:2011
- 资助金额:
$ 111.95万 - 项目类别:
Discovery Projects
EAPSI: Enhanced Delivery of Anti-Tubercular Nanoscale Drug Cocktails Through Aerosol Formulation
EAPSI:通过气雾剂配方增强抗结核纳米级药物混合物的输送
- 批准号:
1015344 - 财政年份:2010
- 资助金额:
$ 111.95万 - 项目类别:
Fellowship Award